RCT1100

DRUG3 trials

Sponsors

ReCode Therapeutics

Conditions

Primary Ciliary DyskinesiaPrimary Ciliary Dyskinesia (PCD)

Phase 1

Study Evaluating the Safety and Tolerability of RCT1100 in Healthy and PCD Subjects

CompletedNCT05737485

ReCode TherapeuticsPrimary Ciliary Dyskinesia

Start: 2023-02-18End: 2025-01-13Updated: 2025-04-29

A Study to Assess the Safety, Tolerability, Ciliary Rescue, and Pharmacodynamics of RCT1100 in Adults With PCD

CompletedNCT06600425

ReCode TherapeuticsPrimary Ciliary Dyskinesia

Start: 2024-09-20End: 2025-08-27Updated: 2025-10-08

Study of Inhaled RCT1100 in Adults With PCD Caused by Pathogenic Mutations in the DNAI1 Gene to Measure Mucociliary Clearance

CompletedNCT06633757

ReCode TherapeuticsPrimary Ciliary Dyskinesia (PCD)

Start: 2024-10-22End: 2026-02-10Updated: 2026-04-30